The 2026 Mid-Year Lab Reimbursement Review: PAMA Reporting Is Closing. Here's What Comes Next

If you run a clinical laboratory, this month marks a turning point. The PAMA private payor data reporting window, running May 1 through July 31, 2026, is closing now. What labs submit to CMS this summer will directly determine Medicare Clinical Laboratory Fee Schedule (CLFS) reimbursement rates beginning January 1, 2027.

And if Congress doesn't act, those rates could mean cuts of up to 15% on nearly 800 laboratory tests.

Here's everything you need to know about where things stand right now, what legislation is in play, and what your lab should be doing to protect revenue heading into 2027.

➡️ Don't wait to find out what 2027 looks like for your lab. Talk to an ADS specialist today.

What's Happening Right Now: The PAMA Reporting Window Is Closing

Under the Protecting Access to Medicare Act of 2014 (PAMA), applicable clinical laboratories, including independent labs, hospital outreach labs, and physician office labs (POLs), are required to report private payor rates and test volumes to CMS. Those weighted medians become the foundation for Medicare CLFS payment rates.

This year's reporting window runs May 1 through July 31, 2026. It uses 2025 commercial market data, a meaningful improvement over the prior cycle, which would have relied on 2019 pre-pandemic rates. That update was mandated by the Consolidated Appropriations Act, 2026, signed into law in February 2026.

Once the window closes and CMS calculates the weighted medians from this data, new CLFS rates go live January 1, 2027.

If your lab hasn't already evaluated its 2027 revenue exposure, now is the time. Explore ADS laboratory billing solutions and learn how we help labs protect revenue in shifting reimbursement environments.

The History That Got Us Here

PAMA has been a slow-moving crisis for clinical laboratories since its implementation in 2018. The law was originally designed to align Medicare payment rates with private market rates, but the first round of data collection captured fewer than 1% of laboratories, primarily large commercial labs, while excluding most hospital outreach labs and significantly undersampling physician office labs.

The result: rates that were artificially deflated, leading to three consecutive years of up to 10% cuts from 2018 through 2020, totaling nearly $4 billion in lost reimbursement across the industry.

Congress has intervened seven times on a bipartisan basis to delay further cuts. Each year, the lab industry held its breath waiting for a permanent fix. Each year, a temporary patch arrived.

2026 is no different, so far.

The February 2026 Patch: What It Did and Didn't Do

The Consolidated Appropriations Act, 2026 provided one more year of relief. This is what the patch changed, and what it left unresolved.

• Rate cuts blocked through December 31, 2026: reductions of up to 15% on nearly 800 tests were delayed
• Data collection updated: replaced outdated 2019 baseline with January 1 through June 30, 2025 data
• Reporting window shifted: moved to May 1 to July 31, 2026

This was the seventh congressional intervention. It helped. But it solved nothing permanently.

Critically, the CBO now scores temporary PAMA delays as costing money rather than saving it, a change from prior years when short-term delays were seen as budget offsets. That scoring shift makes it harder to pass another one-year patch, and makes a permanent legislative fix more politically attractive.

The question labs shouldn't be asking is "will we get another delay?" The question is: what happens to our revenue if we don't?

Schedule a consultation with ADS to model your 2027 reimbursement exposure.

SALSA Is Gone. The RESULTS Act Is the Permanent Fix Now

For several years, the Saving Access to Laboratory Services Act (SALSA) was the primary legislative vehicle for permanent PAMA reform. It gained bipartisan support and significant co-sponsorship but never passed.

In September 2025, SALSA was effectively replaced by the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, introduced with bipartisan, bicameral support.

What the RESULTS Act Would Do

The RESULTS Act addresses the structural problems that have made PAMA unpredictable since 2018. Here is what it changes.

• Fixes the data problem permanently. Instead of relying on labs to self-report private payor rates, a process that historically captured a skewed, unrepresentative sample, the RESULTS Act directs CMS to work with an independent not-for-profit commercial payor database that already contains comprehensive private market data from across the laboratory sector
• Freezes rates and cancels pending cuts during the implementation period, protecting labs from the 2027 cliff while the new methodology is built out
• Caps future reductions at 5% per year once fully implemented, down from the current 15% cap, creating meaningful rate stability for the first time under PAMA
• Excludes Medicaid managed care rates from CLFS calculations, a longstanding industry concern, since Medicaid rates are not true market-based rates and have artificially suppressed Medicare reimbursement
• Reduces administrative burden. Labs would no longer need to submit private payor data for widely available tests. CMS would pull it from the third-party database, dramatically reducing reporting overhead

Full implementation: 2029, with new rates based on 2027 data.

Where the RESULTS Act Stands Right Now

As of mid-2026, the RESULTS Act has cleared committee hearings and carries strong bipartisan co-sponsorship in both chambers. It has not yet been passed into law. Congress would need to act before year-end 2026 to prevent the 2027 cuts from taking effect.

The pathway to passage is not guaranteed. The CBO scoring shift that made temporary patches more expensive does improve the RESULTS Act's political viability, but labs cannot plan around legislative hope alone.

Regardless of what Congress does, your revenue cycle needs to be airtight heading into 2027. See how ADS helps labs stay ahead of reimbursement changes.

The 2027 Cliff: What's at Stake

If Congress does not pass the RESULTS Act or enact another delay before December 31, 2026, the impact reaches beyond a single fee schedule update.

• CLFS reimbursement rates drop by up to 15% on approximately 800 tests starting January 1, 2027
• Rates will be based on the 2025 data currently being submitted, better than 2019, but still subject to PAMA's structural flaws
• Community and independent labs, which operate on thinner margins than large commercial reference labs, face the most acute risk
• Rural and underserved communities, where independent labs are often the only option for routine diagnostics, face potential access gaps

Since 2018, Medicare has paid approximately $4 billion less for laboratory services than it did before PAMA cuts began. Many commonly ordered tests, including complete blood count, basic metabolic panel, and lipid panels, have seen cumulative reductions of 30% or more.

Labs that are already running tight revenue cycles will feel a 15% cut. Labs that are leaving money on the table may not survive it.

Find out where your lab stands. Connect with an ADS lab billing expert.

What This Means for Your Lab's Revenue Cycle Right Now

Whether the RESULTS Act passes or another patch buys time, the lesson of the past eight years is clear: labs with tight revenue cycle controls, clean billing, strong denial management, and optimized coding are better positioned to absorb reimbursement pressure than those operating with inefficiency.

Common revenue cycle gaps show up in the same places across most clinical labs. Recognizing them is the first step toward closing them before the 2027 rate change arrives.

• Undercoded or miscoded tests: especially as new CPT codes are introduced for molecular and specialty diagnostics
• Underpayment from commercial payers: private payor rates are negotiable; many labs accept rates without benchmarking against the market
• Denial backlogs: labs without systematic denial tracking and appeals workflows lose recoverable revenue every month
• Slow credentialing and payer enrollment: delays in enrolling new providers or locations mean lost billing windows
• Manual billing workflows: increasing claim volumes demand automation; manual processes create lag and errors that compound over time

If any of these sound familiar, you're not alone, and you're not out of options. ADS works with independent, hospital outreach, and specialty labs to close these gaps before they become crisis points.

Mid-Year Checklist: What Labs Should Do Before Year-End

With six months left in 2026 and a 2027 inflection point on the horizon, now is the time to assess and strengthen your revenue cycle infrastructure.

1. Audit your CLFS exposure.
Pull your top 50 test codes by Medicare volume and map them against the CLFS. Identify which are among the ~800 tests most likely to face cuts. Understand your 2027 revenue risk before it arrives. ADS can help you run this analysis.

2. Benchmark your denial rate.
Industry standard is below 5%. If you don't know your current denial rate by payer, by test category, and by reason code, you have a gap. See how ADS denial management tools surface these patterns in real time.

3. Review your private payor contracts.
If your commercial rates are based on Medicare CLFS multipliers, a Medicare cut flows directly through to private revenue. Negotiate fixed rates or carve out CLFS-linked language where possible. Talk to an ADS specialist about contract benchmarking.

4. Evaluate your RCM technology stack.
Manual claims management cannot keep pace with the complexity and volume of modern lab billing. If you're not using a purpose-built lab billing platform, you're likely missing recoverable revenue. Compare MedicsPremier for in-house automation and ADSRCM for fully outsourced lab billing.

5. Credential proactively.
If you're planning to expand locations or add providers in 2027, start the enrollment process now. Payer credentialing timelines are long and delays mean lost billing windows from day one.

The Bottom Line

The PAMA reporting window is closing. The 2027 clock is running. The RESULTS Act is real progress toward permanent reform, but it hasn't passed yet. Labs are in a familiar position: genuine legislative hope, genuine near-term risk, and a narrow window to prepare.

The labs that treat the next six months as a revenue cycle strengthening period, rather than a waiting period, will be better positioned regardless of what Congress does.

Your lab can't control what Congress does. You can control how strong your revenue cycle is when January 1, 2027 arrives.

Schedule a consultation with Advanced Data Systems today and see what your lab could be capturing that it isn't.